An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Number of Adverse Events (AEs)
研究概览
简要总结
The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system and to test whether the AID System functions as designed. The study will last about 3 months with up to 6 days of inpatient time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Have known allergies or history of hypersensitivity to insulin lispro
- •Have had an episode of severe hypoglycemia within the past 6 months
- •Have had more than 1 episode of diabetic ketoacidosis in the past 6 months
研究组 & 干预措施
AID System Containing Insulin Lispro
The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
干预措施: Insulin Lispro (Drug)
AID System Containing Insulin Lispro
The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
干预措施: AID System (Device)
结局指标
主要结局
Number of Adverse Events (AEs)
时间窗: In-Patient Period (6 Days)
Number of AEs
Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL
时间窗: In-Patient Period (6 Days)
CGM measured percentage of time \<70 milligrams per deciliter (mg/dL)
次要结局
未报告次要终点